Disclosures for "Investigating the Effects of Brain Cholesterol Metabolism Using CYP46A1 Gene Therapy in Subjects with Huntington’s Disease")
-
Dr. Schultz has received personal compensation for serving as an employee of AskBio.
-
The institution of Dr. Durr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. The institution of Dr. Durr has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics. The institution of Dr. Durr has received research support from NIH. The institution of Dr. Durr has received research support from BIOGEN. The institution of Dr. Durr has received research support from MINORYX. The institution of Dr. Durr has received research support from TRIPLETS THERAPEUTICS. The institution of Dr. Durr has received research support from Servier. The institution of Dr. Durr has received research support from ANR. The institution of Dr. Durr has received research support from PTC.
-
Prof. Karachi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston scientific / Medtronic / Neurotrials.
-
Dr. O'Callaghan has received personal compensation for serving as an employee of Asklepios Biopharmaceuticals. Dr. O'Callaghan has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Asklepios Biopharmaceuticals. Dr. O'Callaghan has stock in Asklepios Biopharmaceuticals. Dr. O'Callaghan has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. ALVES has nothing to disclose.
-
Dr. Lamontagne has received personal compensation for serving as an employee of Asklepios Biopharmaceutical Inc.
-
Mrs. HURMIC has nothing to disclose.
-
Dr. Cartier has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for askbio. Dr. Cartier has stock in brainvectis.